Daiichi Sankyo Joins SCRS Global Impact Partner Program
Hanover, MD, September 19, 2022 – The Society for Clinical Research Sites (SCRS) today announced a Global Impact Partnership with Daiichi Sankyo, a global pharmaceutical company based in Japan creating new standards of care through drug research and development. As a Global Impact Partner (GIP), Daiichi Sankyo will engage with SCRS and its members to contribute to the development and implementation of site and patient-focused solutions for the clinical research marketplace.
Sean Soth, SCRS Senior Vice President of Strategy & Global Business Partnerships commented, “SCRS is pleased to welcome Daiichi Sankyo to the SCRS Global Impact Partner program. From the start, the Daiichi Sankyo team has provided valuable insights into their approach to site relationships, attending Summits and inviting their global team to understand more about the work SCRS and site members are conducting every day. We look forward to sharing new experiences with Daiichi Sankyo and our community for years to come.”
“At Daiichi Sankyo, our success relies on experts in partnership—our people, scientists, health care providers and advocates. Every practitioner, each passionately bringing their own skill to bear, is essential. Clinical trial sites are the critical link between our science and the people we seek to help, and being a part of the Society for Clinical Research Sites is an important connection to support smooth, effective and efficient trials that will help us change standards of care,” said Kristine Koontz, PhD, MBA,VP of Global Clinical Operations at Daiihi Sankyo.
About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.
About The Society for Clinical Research Sites
Founded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit MySCRS.org.
Contact:
Marissa Hill
Communications Manager
Society for Clinical Research Sites
communications@myscrs.org
410.696.5080
